Company intelligence / Profile preview

sBioMed

Orem, Utah, United States

Ownership: Private
Development stage: Other

Overview

sBioMed has developed Steriplex SD, a patented antimicrobial solution designed to kill Clostridium difficile, a healthcare-associated infection. The company describes it as a "non-fuming and non-corrosive" green alternative to bleach, developed after a decade of research, over 500 studies, and EPA registration. As of the available information, the company was entering full-scale commercialization.

Therapeutic areas: Infectious Diseases
Modalities: Small molecule (antimicrobial chemistry)
Industry: Biotech

Beyond the preview

Go deeper on sBioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sBioMed.

Explore the full profile